The global auto injector market by product type, therapy type, indication, route of distribution, end user & regions
The global autoinjectors market is projected to reach USD 153.1 billion by 2027 from USD 40.1 billion in 2019, at a CAGR of 18.2% from 2019 to 2027. Market growth is largely driven by the growing prevalence of targeted therapies, the rising incidence of anaphylaxis, rising preference for self-administration of drugs, usability advantages, the increasing number of regulatory approvals, the availability of generic versions of autoinjectors, favourable reimbursements and government support, and technological advancements. The patent expiry of biologics is also expected to provide growth opportunities for players in the market.
On the other hand, the preference for alternative routes of drug delivery such as oral diabetic agents and nasal epinephrine sprays is expected to limit the adoption of autoinjector devices. Some of the key players operating in the autoinjectors market include AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany).
The COVID-19 pandemic has resulted in a global healthcare crisis, causing a shift in healthcare delivery in most regions. Moreover, the slowdown in clinical trial recruitment has delayed the introduction of new therapies. These factors could have had a negative impact on the autoinjectors market, especially with their use in healthcare institutions in early 2020. However, the pandemic’s overall effect on the autoinjectors is considered positive, especially in the forecast period, due to several factors. Firstly, the demand for effective home care and remote monitoring has increased the relevance of autoinjectors for patients to conveniently and easily manage chronic illnesses and allergies without visiting the hospital. This has been especially true in the case of diabetes, Crohn’s disease, a rheumatoid arthritis patient relying on prefilled syringes and autoinjectors to manage their condition at home.
The autoinjectors market, by therapy, is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, multiple sclerosis, and other therapies (includes cardiovascular diseases, migraine treatment, anaemia, and progesterone therapy). In 2019, rheumatoid arthritis accounted for the largest share of autoinjectors market. The large share of this segment is mainly attributed to its high prevalence. The increasing incidence of RA fuels the demand for autoinjectors for this therapy segment. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US are affected annually by some form of arthritis, RA, gout, lupus, or fibromyalgia.
Based on type, the autoinjectors market is segmented into reusable and disposable autoinjectors. In 2018, the disposable autoinjectors segment accounted for the largest share of the global autoinjectors market. Disposable autoinjectors are the most-preferred autoinjectors due to their ease of use and the presence of a built-in glass syringe (eliminates the need of manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairments.
Based on route of administration, the autoinjectors market is segmented intramuscular and subcutaneous. Patients use autoinjectors for intramuscular and subcutaneous administration of various drugs for the treatment of diseases such as rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, anaemia, and cancer. The subcutaneous segment accounted for the largest share and it is expected to witness fastest growth during the forecast period. The large share of this segment can primarily be attributed to the growing number of product approvals by regulatory bodies for the treatment of chronic diseases.
Based on end users, the autoinjectors market is segmented into home care settings, hospitals & clinics, and ambulatory care settings. The home care settings segment accounted for the largest share of the autoinjectors market in 2018. The large share of this end-user segment can primarily be attributed to the rapid growth in the geriatric population across the globe and the growing need for cost-effective drug administration.
Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is majorly driven by the large diabetes population and increasing healthcare expenditure which has drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies.
On the other hand, the preference for alternative routes of drug delivery such as oral diabetic agents and nasal epinephrine sprays is expected to limit the adoption of autoinjector devices. Some of the key players operating in the autoinjectors market include AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany).
The COVID-19 pandemic has resulted in a global healthcare crisis, causing a shift in healthcare delivery in most regions. Moreover, the slowdown in clinical trial recruitment has delayed the introduction of new therapies. These factors could have had a negative impact on the autoinjectors market, especially with their use in healthcare institutions in early 2020. However, the pandemic’s overall effect on the autoinjectors is considered positive, especially in the forecast period, due to several factors. Firstly, the demand for effective home care and remote monitoring has increased the relevance of autoinjectors for patients to conveniently and easily manage chronic illnesses and allergies without visiting the hospital. This has been especially true in the case of diabetes, Crohn’s disease, a rheumatoid arthritis patient relying on prefilled syringes and autoinjectors to manage their condition at home.
The autoinjectors market, by therapy, is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, multiple sclerosis, and other therapies (includes cardiovascular diseases, migraine treatment, anaemia, and progesterone therapy). In 2019, rheumatoid arthritis accounted for the largest share of autoinjectors market. The large share of this segment is mainly attributed to its high prevalence. The increasing incidence of RA fuels the demand for autoinjectors for this therapy segment. According to the CDC, an estimated 43.7 million adults (22.7% of the total population) in the US are affected annually by some form of arthritis, RA, gout, lupus, or fibromyalgia.
Based on type, the autoinjectors market is segmented into reusable and disposable autoinjectors. In 2018, the disposable autoinjectors segment accounted for the largest share of the global autoinjectors market. Disposable autoinjectors are the most-preferred autoinjectors due to their ease of use and the presence of a built-in glass syringe (eliminates the need of manually loading the glass syringe), which makes it more convenient for patients with reduced dexterity or visual impairments.
Based on route of administration, the autoinjectors market is segmented intramuscular and subcutaneous. Patients use autoinjectors for intramuscular and subcutaneous administration of various drugs for the treatment of diseases such as rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, migraine, anaemia, and cancer. The subcutaneous segment accounted for the largest share and it is expected to witness fastest growth during the forecast period. The large share of this segment can primarily be attributed to the growing number of product approvals by regulatory bodies for the treatment of chronic diseases.
Based on end users, the autoinjectors market is segmented into home care settings, hospitals & clinics, and ambulatory care settings. The home care settings segment accounted for the largest share of the autoinjectors market in 2018. The large share of this end-user segment can primarily be attributed to the rapid growth in the geriatric population across the globe and the growing need for cost-effective drug administration.
Geographically, the autoinjectors market is segmented into North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. Growth in the Asia Pacific market is majorly driven by the large diabetes population and increasing healthcare expenditure which has drawn a number of major autoinjector device manufacturers to this region. These companies are increasing their presence in the Asia Pacific market through several approaches, such as establishing sales offices and partnering with local pharmaceutical companies.
1. INTRODUCTION
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. PREMIUM INSIGHTS
5. MARKET OVERVIEW
1) INTRODUCTION
2) MARKET DYNAMICS
i. Drivers
ii. Restraints
iii. Opportunities
iv. Challenges
3) COVID-19 IMPACT OF THE AUTOINJECTORS MARKET
6. INDUSTRY INSIGHTS
1) INTRODUCTION
2) INDUSTRY TRENDS
7. AUTOINJECTORS MARKET, BY THERAPY, 2020-2027 (USD MILLION)
1) RHEUMATOID ARTHRITIS
2) DIABETES
3) MULTIPLE SCLEROSIS
4) ANAPHYLAXIS
5) OTHER THERAPIES
8. AUTOINJECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
1) DISPOSABLE AUTOINJECTORS
2) REUSABLE AUTOINJECTORS
9. AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
1) SUBCUTANEOUS
2) INTRAMUSCULAR
10. AUTOINJECTORS MARKET, BY END USER, 2020-2027 (USD MILLION)
1) HOME CARE
2) HOSPITALS & CLINICS
3) AMBULATORY CARE SETTINGS
11. AUTOINJECTORS MARKET, BY GEOGRAPHY, 2020-2027 (USD MILLION)
1) NORTH AMERICA
i. US
ii. Canada
2) EUROPE
i. Germany
ii. UK
iii. France
iv. Italy
v. Spain
vi. Rest of Europe
3) ASIA-PACIFIC
i. China
ii. Japan
iii. India
iv. Rest of Asia-Pacific
4) LATIN AMERICA
5) MIDDLE EAST AND AFRICA
12. COMPETITIVE LANDSCAPE
1) INTRODUCTION
2) COMPETITIVE SITUATION AND TRENDS
i. Product Launches
ii. Partnerships, Collaborations, and Agreements
iii. Acquisitions
iv. Expansions
v. Other Developments
13. COMPANY PROFILES
1) ABBVIE INC.
2) AMGEN
3) ELLI LILLY AND COMPANY
4) MYLAN
5) YPSOMED
6) BECTON, DICKINSON, AND COMPANY
7) GLAXOSMITHKLINE PLC.
8) JOHNSON & JOHNSON
9) TEVA PHARMACEUTICAL INDUSTRIES
10) ANTARES PHARMA, INC.
11) MERCK KGAA
12) MERIDIAN MEDICAL TECHNOLOGIES, INC.
13) ROCHE
14) BESPAK
15) BAYER AG
16) BRISTOL-MYERS SQUIBB COMPANY
17) SHL MEDICAL
18) HASELMETER
19) OWEN MUMFORD
20) RAVIMED
14. APPENDIX
1) DISCUSSION GUIDE
2) AVAILABLE CUSTOMIZATIONS
3) RELATED REPORTS
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. PREMIUM INSIGHTS
5. MARKET OVERVIEW
1) INTRODUCTION
2) MARKET DYNAMICS
i. Drivers
ii. Restraints
iii. Opportunities
iv. Challenges
3) COVID-19 IMPACT OF THE AUTOINJECTORS MARKET
6. INDUSTRY INSIGHTS
1) INTRODUCTION
2) INDUSTRY TRENDS
7. AUTOINJECTORS MARKET, BY THERAPY, 2020-2027 (USD MILLION)
1) RHEUMATOID ARTHRITIS
2) DIABETES
3) MULTIPLE SCLEROSIS
4) ANAPHYLAXIS
5) OTHER THERAPIES
8. AUTOINJECTORS MARKET, BY TYPE, 2020-2027 (USD MILLION)
1) DISPOSABLE AUTOINJECTORS
2) REUSABLE AUTOINJECTORS
9. AUTOINJECTORS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2027 (USD MILLION)
1) SUBCUTANEOUS
2) INTRAMUSCULAR
10. AUTOINJECTORS MARKET, BY END USER, 2020-2027 (USD MILLION)
1) HOME CARE
2) HOSPITALS & CLINICS
3) AMBULATORY CARE SETTINGS
11. AUTOINJECTORS MARKET, BY GEOGRAPHY, 2020-2027 (USD MILLION)
1) NORTH AMERICA
i. US
ii. Canada
2) EUROPE
i. Germany
ii. UK
iii. France
iv. Italy
v. Spain
vi. Rest of Europe
3) ASIA-PACIFIC
i. China
ii. Japan
iii. India
iv. Rest of Asia-Pacific
4) LATIN AMERICA
5) MIDDLE EAST AND AFRICA
12. COMPETITIVE LANDSCAPE
1) INTRODUCTION
2) COMPETITIVE SITUATION AND TRENDS
i. Product Launches
ii. Partnerships, Collaborations, and Agreements
iii. Acquisitions
iv. Expansions
v. Other Developments
13. COMPANY PROFILES
1) ABBVIE INC.
2) AMGEN
3) ELLI LILLY AND COMPANY
4) MYLAN
5) YPSOMED
6) BECTON, DICKINSON, AND COMPANY
7) GLAXOSMITHKLINE PLC.
8) JOHNSON & JOHNSON
9) TEVA PHARMACEUTICAL INDUSTRIES
10) ANTARES PHARMA, INC.
11) MERCK KGAA
12) MERIDIAN MEDICAL TECHNOLOGIES, INC.
13) ROCHE
14) BESPAK
15) BAYER AG
16) BRISTOL-MYERS SQUIBB COMPANY
17) SHL MEDICAL
18) HASELMETER
19) OWEN MUMFORD
20) RAVIMED
14. APPENDIX
1) DISCUSSION GUIDE
2) AVAILABLE CUSTOMIZATIONS
3) RELATED REPORTS
